Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
V504 · 1 trial · 5 indications
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | V504 + Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine |
| 2 | PLACEBO_COMPARATOR | Placebo + Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine |
| Name | Type | Description |
|---|---|---|
| V504 | BIOLOGICAL | V504 0.5 ml injection in 3 dose regimen for 6 month treatment period. |
| Comparator: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine | BIOLOGICAL | Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine 0.5 ml injection in 3 dose regimen for 6 month treatment period. |
| Comparator: Placebo (unspecified) | BIOLOGICAL | V504 Placebo in 3 dose regimen for 6 month treatment period. |
Inclusion Criteria: * Females between 16- to 26-years-old * Has never had Pap testing or has only had normal Pap test results. * Lifetime history of 0 to 4 sexual partners Exclusion Criteria: * History of an abnormal cervical biopsy result * History of a positive test for HPV; History of external...
Top 20 of 27 competitors
V504 is an investigational monoclonal antibody being studied for use in cervical cancer. It is also being evaluated in the context of human papillomavirus infection, genital warts, vulvar cancer, and vaginal cancer. The drug is currently in Phase 2 clinical development.
V504 is being developed by Merck & Company, Inc., which trades under the ticker MRK. The company is conducting clinical trials to evaluate the drug's safety and efficacy in oncology and infectious disease settings.
V504 is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The drug is being studied in a completed Phase 2 trial that evaluated its tolerability and immunogenicity.
V504 has one completed clinical trial, identified as NCT00551187. This Phase 2 study evaluated the tolerability and immunogenicity of V504 when administered concomitantly with GARDASIL. The trial enrolled 620 female participants aged 16 years and older.
No, V504 is not the same as GARDASIL. V504 is an investigational monoclonal antibody, while GARDASIL is a vaccine. In the clinical trial NCT00551187, V504 was administered concomitantly with GARDASIL to evaluate their combined use.